Institute for Policy Innovation

Lewisville, TX 75057

Tim Lambert
June 22, 2004

When Think Tanks Attack

Think tanks vs Open Source

The Alexis de Tocqueville Institute’s attack on Linux is just the latest in a series of attacks on Open Source by think tanks:

Tony Healy of IPI: Has Open Source Reached Its Limits?

The reality is that open source can trap a customer into an outsourcer relationship more readily than commercial software. This is because commercial platforms expose standard API’s for third party applications and any consultant can develop for them ... open source will go the way of other IT industry fads that were once trumpeted as the way of the future, like Macintosh computers, business AI, 4GL programming languages and Y2K.

Also see:

CSE, Aug 27, 2003, Wayne T. Brough: New Protectionism: Mandates for Open Source Software

Read the full report >

Conservative Philanthropy supported institutions involved in the attack on Open Source

* Competitive Enterprise Institute
* Washington Legal Foundation
* Defenders of Property Rights
* Pacific Research Institute
* Citizens for a Sound Economy
* Institute for Policy Innovation
* Alexis de Tocqueville Institute

Printer friendly
sign in, or register to email profiles or comment on them.

On Opinion Page, a Lobby's Hand Is Often Unseen

Susan Finston of the Institute for Policy Innovation...is just the sort of opinion maker coveted by the drug industry.

In an opinion article in The Financial Times on Oct. 25, she called for patent protection in poor countries for drugs and biotechnology products. In an article last month in the European edition of The Wall Street Journal, she called for efforts to block developing nations from violating patents on AIDS medicines and other drugs.Both articles identified her as a "research associate" at the institute. Neither mentioned that, as recently as August, Ms. Finston was registered as a lobbyist for the Pharmaceutical Research and Manufacturers of America, the drug industry's trade group. Nor was there mention of her work this fall in creating the American Bioindustry Alliance, a group underwritten largely by drug companies.

Read the full report >

RELATED LINKS

Internal Links

External Links

RECIPIENT PROFILE